These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 31290965

  • 1. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB.
    Int J Neuropsychopharmacol; 2019 Oct 01; 22(10):616-630. PubMed ID: 31290965
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC.
    JAMA Psychiatry; 2018 Feb 01; 75(2):139-148. PubMed ID: 29282469
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.
    JAMA Psychiatry; 2019 Sep 01; 76(9):893-903. PubMed ID: 31166571
    [Abstract] [Full Text] [Related]

  • 5. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB.
    J Clin Psychiatry; 2020 Apr 28; 81(3):. PubMed ID: 32316080
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB.
    Am J Geriatr Psychiatry; 2020 Feb 28; 28(2):121-141. PubMed ID: 31734084
    [Abstract] [Full Text] [Related]

  • 7. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM.
    J Clin Psychiatry; 2020 May 12; 81(3):. PubMed ID: 32412700
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y.
    BMC Psychiatry; 2021 Oct 25; 21(1):526. PubMed ID: 34696742
    [Abstract] [Full Text] [Related]

  • 9. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T, Wajs E, Melkote R, Miller J, Singh JB, Weber MA.
    CNS Drugs; 2020 Mar 25; 34(3):299-310. PubMed ID: 31994024
    [Abstract] [Full Text] [Related]

  • 10. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M, Wajs E, Aluisio L, Turkoz I, Daly E, Janik A, Borentain S, Singh JB, DiBernardo A, Wiegand F.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):426-433. PubMed ID: 32270176
    [Abstract] [Full Text] [Related]

  • 11. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
    Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM.
    Int J Neuropsychopharmacol; 2021 Jan 20; 24(1):22-31. PubMed ID: 32861217
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR, Freeman MP, Kornstein SG, Cooper K, Daly EJ, Canuso CM, Nicholson S.
    Arch Womens Ment Health; 2022 Apr 20; 25(2):313-326. PubMed ID: 34973081
    [Abstract] [Full Text] [Related]

  • 13. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL, Popova V, Wylie C, Fedgchin M, Daly E, Janik A, Ochs-Ross R, Lane R, Lim P, Cooper K, Melkote R, Jamieson C, Singh J, Drevets WC.
    CNS Drugs; 2021 Jul 20; 35(7):781-794. PubMed ID: 34235612
    [Abstract] [Full Text] [Related]

  • 14. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
    Targum SD, Daly E, Fedgchin M, Cooper K, Singh JB.
    J Psychiatr Res; 2019 Apr 20; 111():68-73. PubMed ID: 30685564
    [Abstract] [Full Text] [Related]

  • 15. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
    Saad Z, Hibar D, Fedgchin M, Popova V, Furey ML, Singh JB, Kolb H, Drevets WC, Chen G.
    Int J Neuropsychopharmacol; 2020 Dec 03; 23(9):549-558. PubMed ID: 32367114
    [Abstract] [Full Text] [Related]

  • 16. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM, Crouse EL, Titus-Lay EN, Ott CA, Nofziger JL, Kirkwood CK.
    Ann Pharmacother; 2020 Jun 03; 54(6):567-576. PubMed ID: 31795735
    [Abstract] [Full Text] [Related]

  • 17. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
    Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L.
    Biol Psychiatry; 2016 Sep 15; 80(6):424-431. PubMed ID: 26707087
    [Abstract] [Full Text] [Related]

  • 18. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
    Turkoz I, Daly E, Singh J, Lin X, Tymofyeyev Y, Williamson D, Salvadore G, Nash AI, Macaluso M, Wilkinson ST, Nelson JC.
    J Clin Psychiatry; 2021 Jul 20; 82(4):. PubMed ID: 34288609
    [Abstract] [Full Text] [Related]

  • 19. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, Drevets WC, Cooper K, Lane R, Singh J.
    J Affect Disord; 2021 Feb 15; 281():767-775. PubMed ID: 33261932
    [Abstract] [Full Text] [Related]

  • 20. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M, Bartova L, Kasper S.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):440-445. PubMed ID: 32570275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.